Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Herantis Pharma (Finland) | Researchclopedia

Back to institutions

Herantis Pharma (Finland)

Helsinkicompany

27

Works

1,053

Citations

19

h-index

Top Research Topics

Nerve injury and regeneration Parkinson's Disease Mechanisms and Treatments Neurological disorders and treatments

Top Researchers

Magnus Sjögren Sundsvall Municipality

210 works11,258 citationsh-index: 54

Recent Research

Cerebral dopamine neurotrophic factor and its functional fragments induce calcium signal through sigma-1 receptor and protect neurons against glutamate-induced excitotoxicity

Nafisa Komilova,Noemi Esteras,et al.

20260 citations

Visual perception and processing mechanisms

Retinal Development and Disorders

Endoplasmic Reticulum Stress and Disease

Signaling Pathways in Disease

Ophthalmology and Visual Impairment Studies

Neuroinflammation and Neurodegeneration Mechanisms

Lymphatic System and Diseases

Intracerebral and Subarachnoid Hemorrhage Research

Nuclear Receptors and Signaling

Kira M. Holmström Herantis Pharma (Finland)

39 works9,557 citationsh-index: 24

Henri J. Huttunen Herantis Pharma (Finland)

86 works5,126 citationsh-index: 35

Arnab Bhattacharjee

66 works3,014 citationsh-index: 14

Natalia Kulesskaya Herantis Pharma (Finland)

56 works1,925 citationsh-index: 24

Mia Engström Malmö University

15 works706 citationsh-index: 12

Identification of receptor binding proteins of Yersinia phage φR1-37 and enterocoliticin that use the same bacterial surface receptor

Arnab Bhattacharjee,Göran Widmalm,et al.

20260 citations

Identification of receptor binding proteins of Yersinia phage φR1-37 and enterocoliticin that use the same bacterial surface receptor

Arnab Bhattacharjee,Göran Widmalm,et al.

20260 citations

Neurotrophic factors for Parkinson's disease: Current status, progress, and remaining questions. Conclusions from a 2023 workshop

Roger A. Barker,Märt Saarma,et al.

20247 citations

Structural basis of CDNF interaction with the UPR regulator GRP78

Melissa A. Graewert,Maria S. Volkova,et al.

20249 citations

Symptomatic vs. Disease-modifying treatments in neurological diseases: Where next?

Henri J. Huttunen

20240 citations